Portfolio Companies News
September 29, 2020Aprea Therapeutics Appoints Michael...
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Michael A. Kelly... read more
September 29, 2020Fusion Pharmaceuticals Appoints Mar...
HAMILTON, ON and BOSTON, Sept. 29, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Maria Stahl as chief legal ... read more
September 28, 2020GenSight Biologics Announces Public...
Paris, France, September 28, 2020, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorde... read more
September 25, 2020Invitation – Orexo Digital Therap...
Uppsala, Sweden – September 25, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today invites investors, analysts, and media to attend a teleconference on Thursday October 1, at 3 pm CET. During the event, Orexo will provide an update on the company’s Digital Therapeutics business, a... read more
September 25, 2020Robust effects of VP01 in human idi...
Gothenburg, September 25, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces effects of VP01 on idiopathic pulmonary fibrosis (IPF) patient tissue. Fresh human IPF lung tissue harvested fro... read more
August 05, 2020Q2 2020 General Market Overview
Since the start in 1996, HealthCap funds have invested in 115 portfolio companies.
44 of the portfolio companies have been taken public on nine different markets.
26 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 10 companies with a valuation of USD 1 billion or more.